Renexxion Ireland Ltd
Ken Kengatharan, PhD MBA is a board director and CBO at Renexxion Ireland Ltd, a member of the board of managers at Renexxion, LLC, and the managing general partner at Atheneos Ventures. Ken is also a board member at Apollorion Global, a director at Radix Blend Company, the executive chairman at Helios Orion, the chairman at Auxesia Orion, and the principal pathfinder at Ananke Pathfinder. With a background in cardiovascular pharmacology and biotech finance, Ken has held various leadership roles in biopharmaceutical companies focused on developing novel drugs for rare diseases and orphan diseases. Ken has a strong track record in corporate strategy advisory, venture advising, and guiding healthcare and cleantech companies in their growth.
This person is not in any teams
This person is not in any offices
Renexxion Ireland Ltd
Renexxion Ireland Innovation There is a large unmet medical need for patients with disorders of gastrointestinal motility. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic, 5-HT4 agonist has shown efficacy in a wide range of these disorders. It is estimated that at least 16% of people worldwide suffer from GI-related disorders. Currently approved therapies do not completely address this high therapeutic need. In some cases, there are no approved therapies. Naronapride has the potential to address the major GI indications associated with dysmotility including chronic idiopathic constipation (CIC), irritable bowel syndrome - constipation type (IBSc), functional dyspepsia (FD), gastroparesis (GP), and gastro-esophageal reflux disease (GERD), in particular PPI-resistant GERD where chronic oral treatments are required. Naronapride may also address unmet therapeutic needs in smaller GI-related indications, both chronic and acute. These include Enteral Feeding Intolerance (EFI), acute GP, short bowel syndrome (SBS), and post-operative ileus (POI).